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Summary
Background:  Anticoagulation  therapy  reduces  the  risk  of  thromboembolic  events  by  two-thirds
in patients  with  atrial  ﬁbrillation  (AF).  The  prevalence  of  left  atrial  thrombus  (LAT)  in  AF  patients
with anticoagulation  therapy  has  not  been  fully  investigated.
Purpose:  To  investigate  the  prevalence  of  LAT  and  its  impact  on  the  outcomes  in  patients  with
nonvalvular  AF  after  anticoagulation  therapy.
Methods:  This  study  consisted  of  231  patients  with  nonvalvular  AF  who  had  transthoracic  (TTE)
and transesophageal  echocardiographic  (TEE)  examinations  more  than  3  weeks  after  anticoag-
ulation therapy.  The  clinical  and  echocardiographic  characteristics  were  evaluated.
Results:  LAT  was  observed  in  13  (8.8%)  of  148  patients  with  sub-therapeutic  anticoagula-
tion, and  in  3  (3.6%)  of  83  patients  with  sufﬁcient  anticoagulation.  The  presence  of  LAT
was associated  with  higher  CHADS2 score,  decreased  LA  volume  changes  and  the  presence  of
spontaneous  echocardiographic  contrast  (SEC)  in  patients  with  sub-therapeutic  anticoagulation.
∗ Corresponding author. Tel.: +81 6 6581 2881; fax: +81 6 6584 1807.
E-mail address: h-syouta@mve.biglobe.ne.jp (S. Fukuda).
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Patients  with  LAT  after  sufﬁcient  anticoagulation  were  male  with  permanent  AF  who  had
decreased  left  ventricular  systolic  and  diastolic  function  and  dilated  LA  on  TTE  and  SEC,  and
reduced appendage  ﬂow  velocity  on  TEE.  Patients  with  LAT  had  worse  cardiovascular  outcomes
compared  with  those  without  LAT  (p  =  0.02).
Conclusions:  We  demonstrated  that  LAT  was  a  univariate  risk  factor  associated  with  worse  cardio-
vascular outcomes,  which  was  observed  in  8.8%  of  patients  with  sub-therapeutic  anticoagulation
ﬁcient  anticoagulation.
ardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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mitral  annular  velocity  (e′)  was  also  measured  from  tis-
sue  Doppler  imaging  in  the  septal  wall.  The  ratio  of  E  to
e′ was  then  calculated  (E/e′).and 3.6%  of  patients  with  suf
© 2011  Japanese  College  of  C
Introduction
Nonvalvular  atrial  ﬁbrillation  (AF)  increases  in  prevalence
as  the  population  ages  [1],  which  increases  the  long-term
risk  of  stroke  and  mortality  from  all  causes  [2—4]. Anticoag-
ulation  therapy  reduces  the  risk  of  thromboembolic  events
by  two-thirds  in  patients  with  AF  [5,6]  indicating  that,  in
some  AF  patients,  it  may  not  be  effective  in  preventing
thromboembolic  events.  The  left  atrium  (LA),  especially
its  appendage,  is  the  presumed  site  of  thrombus  forma-
tion  as  a  result  of  blood  stasis,  which  is  thought  to  cause
stroke  in  patients  with  AF  [7—12]. Anticoagulation  therapy
is  controlled  for  international  normalized  ratio  (INR)  of  2.0
in  elderly  patients  and  2.5  for  younger  patients  in  West-
ern  countries  [13,14].  In  contrast,  anticoagulation  therapy
is  controlled  for  INR  between  2.0  and  3.0  in  patients  with
ages  of  younger  than  70  years,  and  between  1.6  and  2.6
in  patients  with  ages  of  70  years  or  older  in  the  Japanese
population.  However,  the  incidence  of  LA  thrombus  (LAT)  in
AF  patients  with  anticoagulation  therapy  has  not  been  fully
investigated,  especially  in  association  with  whether  sufﬁ-
cient  anticoagulation  therapy  with  INR  greater  than  or  equal
to  2.0  for  at  least  3  weeks  is  achieved  or  failed.  Furthermore,
the  impact  of  the  presence  of  LAT  on  the  outcomes  has  not
been  fully  determined.  Therefore,  the  purpose  of  this  study
was  to  investigate  the  clinical  and  echocardiographic  char-
acteristics  of  AF  patients  with  LAT  after  more  than  3  weeks
of  anticoagulation  therapy  and  to  compare  the  outcomes  in
patients  with  and  without  LAT.
Methods
Study  population
The  records  of  231  patients  with  AF  who  had  transthoracic
(TTE)  and  transesophageal  echocardiographic  (TEE)  exam-
inations  more  than  3  weeks  after  anticoagulation  therapy
were  reviewed  at  Osaka  Ekisaikai  Hospital  and  the  Sakak-
ibara  Heart  Institute.  Their  data  were  abstracted  from  the
clinical  and  echocardiography  databases  from  October  2005
to  September  2010,  and  retrospectively  analyzed.  Patients
were  excluded  if  they  had  (1)  history  of  prior  cardiac
surgery,  (2)  moderate  or  more  severe  valvular  diseases,  or
(3)  congenital  heart  disease.  Patients  were  referred  to  TEE
examination  for  decisions  with  regard  to  cardioversion.  No
patients  had  probable  thrombus  on  a  previous  TEE  examina-
tion.The  clinical  risk  factors,  including  ages  of  75  years
or  older,  hypertension,  diabetes,  congestive  heart  fail-
ure,  and  history  of  cerebral  ischemia,  were  evaluated  in
each  individual,  and  then  the  CHADS2 score  was  calculated
515]. Based  on  the  results  of  laboratory  examinations,
atients  were  divided  into  2  groups:  sufﬁcient  antico-
gulation  and  sub-therapeutic  anticoagulation.  When  2
onsecutive  laboratory  examinations  with  the  interval  of
ore  than  3  weeks  showed  INR  greater  than  or  equal
o  2.0,  anticoagulation  therapy  was  considered  as  suf-
cient.  Other  patients  were  classiﬁed  into  the  group
ith  sub-therapeutic  anticoagulation.  The  INR  value  just
efore  TEE  examination  (2  ±  5  days)  was  also  provided.
his  study  was  approved  by  the  ethics  committees  of
saka  Ekisaikai  Hospital  and  the  Sakakibara  Heart  Institute,
espectively.
ransthoracic  echocardiography
wo-dimensional  TTE  was  performed  in  the  standard  man-
er  with  several  commercially  available  echocardiographic
ystems  with  tissue  Doppler  echocardiographic  capabil-
ties;  Sonos  5500  and  IE-33  (Philips  Medical  Systems,
ndover,  MA,  USA),  Sequoia  512  (Siemens,  Mountainview,
A,  USA),  Vivid  7  (GE  Medical  Systems,  Milwaukee,  WI,
SA),  or  Aplio  SSA-770  (Toshiba  Medical  Systems,  Tokyo,
apan).  Echocardiographic  images  were  obtained  in  stan-
ard  parasternal  and  apical  views  and  digitally  stored.  After
arefully  choosing  the  highest  possible  quality  image  and
egular  preceding  R-R  intervals  using  the  digital  storing
ystem,  echocardiographic  measurement  was  reviewed  to
btain  the  following  echocardiographic  parameters  for  this
tudy.
.  Left  ventricular  (LV)  end-diastolic  and  end-systolic  vol-
umes  were  obtained  to  calculate  LV  ejection  fraction
using  Simpson’s  method  from  apical  4-  and  2-chamber
views.
. LV  mass  was  calculated  based  on  the  area—length  formula
[16].
.  Maximum  and  minimum  LA  volumes  were  measured  by
the  Simpson’s  rule  methods  from  apical  4-  and  2-chamber
views.  LA  volume  change  was  calculated  as  (maximum
volume  −  minimum  volume)/maximum  volume  ×  100.
.  Pulsed-wave  Doppler  examination  of  mitral  inﬂow  was
performed  to  measure  peak  velocity  (E)  and  deceler-
ation  time  of  the  early  diastolic  ﬂow.  Early  diastolic.  After  recording  the  tricuspid  systolic  velocity  with
continuous-wave  Doppler,  right  ventricular  (RV)  systolic
pressure  was  calculated  using  the  simpliﬁed  Bernoulli
equation  [17], adding  the  right  atrial  pressure  estimated
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wigure  1  Example  image  of  left  atrial  thrombus  (arrow).  The  t
from  the  diameter  of  the  inferior  vena  cava  during  res-
piration  [18,19].
Each  parameter  was  indexed  for  body  surface  area  when
ppropriate.
ransesophageal  echocardiography
EE  examination  was  performed  under  light  conscious  seda-
ion  and  topical  anesthesia.  An  Aplio  SSA-770,  a  Sonos
500,  or  an  IE-33  incorporated  multiplane  transducer  was
sed.  These  transducers  had  the  capability  of  broadcast  fre-
uency  ranging  approximately  from  2  MHz  to  7  MHz.  LAT,
pontaneous  echocardiographic  contrast  (SEC)  in  the  atrium,
ntra-atrial  shunts,  atrial  septal  aneurysm,  and  aortic  plaque
ere  assessed  as  possible  sources  of  embolisms.  Intra-atrial
hunting  was  estimated  by  intravenous  infusion  of  agitated
aline  and  color  Doppler  method.  Depending  on  the  image
uality,  the  frequency  and  gain  settings  were  carefully
djusted  to  minimize  gray-noise  artifact,  especially  when
ssessing  for  SEC.  Images  evaluating  such  echocardiographic
ndings  were  acquired  using  the  standard  procedure  and  dig-
tally  stored.  A  thrombus  was  deﬁned  as  an  echo  dense  mass,
s  shown  in  Fig.  1.  SEC  was  considered  present  when  dynamic
‘smoke-like’’  echoes  were  seen  in  the  atrium  (Fig.  2).  In
ddition,  the  LA  appendage  ﬂow  velocity  was  also  obtained
y  the  pulsed  Doppler  method  with  the  sample  volume
laced  1  cm  distal  from  the  mouth  of  the  appendage.
t
l
l
p
igure  2  Example  image  of  spontaneous  echocardiographic  contr
ere observed  in  the  left  atrium  and  its  appendage.rrows  indicated  small  pectinate  muscles  within  the  appendage.
tatistical  analysis
alues  are  expressed  as  mean  ±  SD.  Comparisons  of  clinical
nd  echocardiographic  data  between  patients  with  sufﬁcient
nticoagulation  and  with  sub-therapeutic  anticoagulation
ere  made  with  an  unpaired  t-test.  Differences  between
roportions  were  assessed  by  chi-square  analysis.  For  com-
arison  of  3  subgroups  of  patients  divided  into  tertiles  based
n  the  INR  value,  we  used  one-way  analysis  of  variance.  Uni-
ariate  and  multivariate  logistic  regression  analyses  were
erformed  to  identify  predictors  of  the  presence  of  LAT,
nd  cardiovascular  events,  respectively.  The  signiﬁcant  vari-
bles  on  univariate  analysis  were  entered  into  multivariate
tepwise  logistic  regression  analysis.  Cumulative  event  rates
ere  estimated  by  the  Kaplan—Meier  survival  curves,  and
he  log-rank  test  was  used  to  examine  the  impact  of  CHADS2
core  and  LAT  on  the  survival,  respectively.  Differences  were
onsidered  signiﬁcant  at  p  <  0.05.
esults
he  clinical  and  echocardiographic  parameters  of  patients
ith  and  without  LAT  in  all  enrolled  patients  are  summarized
n  Table  1.  The  presence  of  SEC  and  lower  LA  appendage
ow  were  found  as  independent  determinants  for  LAT  in
he  multivariate  analysis.  Patients  with  LAT  tended  to  have
ower  prevalence  of  sufﬁcient  anticoagulation  therapy  and
ower  value  of  INR  than  those  without  LAT  (p  =  0.2).  When
atients  were  divided  into  tertiles  based  on  the  INR  value,
ast.  Dynamic  ‘‘smoke-like’’  echoes  throughout  a  cardiac  cycle
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Table  1  Clinical  and  echocardiographic  parameters  in  patients  with  and  without  LAT  in  all  enrolled  patients.
Overall  (n  =  231) LAT  (+)  (n  =  16) LAT  (−)  (n  =  215)  Univariate  analysis Multivariate  analysis
p-Value Odds  ratio  (95%  CI) p-Value Odds  ratio  (95%  CI)
Age,  years 64  ±  12 71  ±  8 63  ±  12 0.02  1.07  (1.01—1.12) 0.8
Male, n  (%) 183  (79) 12  (75) 171  (80) 0.7  0.77  (0.24—2.51)
Body mass  index 23.4  ±  3.5  23.0  ±  3.8  23.5  ±  3.5  0.6  0.96  (0.82—1.11)
Hypertension,  n  (%) 129  (56%) 10  (63) 119  (55) 0.6  1.35  (0.47—3.83)
Diabetes mellitus,  n  (%) 45  (19) 5  (31) 40  (19) 0.2  1.99  (0.65—6.04)
Heart failure,  n  (%) 89  (39) 10  (63) 79  (37) 0.04  2.87  (1.01—8.19) 0.3
History of  cerebral
ischemia,  n  (%)
33  (14) 4  (25) 29  (13) 0.2  2.14  (0.65—7.08)
CHADS2 score 1.6  ±  1.3  2.5  ±  1.3  1.6  ±  1.3  0.006  1.74  (1.17—2.60) 0.06
Paroxysmal AF,  n  (%) 72  (31) 2  (13) 70  (33) 0.1  0.30  (0.07—1.33)
Duration of  anticoagulation
therapy  (>1  year),  n  (%)
58  (25) 8  (50) 50  (23) 0.02  3.30  (1.18—9.24) 0.06
Sufﬁcient anticoagulation
therapy,  n  (%)
83  (36) 3  (19) 80  (37) 0.2  0.39  (0.11—1.41)
INR 2.1 ±  0.7  1.8  ±  0.4  2.1  ±  0.6  0.2  0.43  (0.13—1.38)
Antiplatelet therapy,  n  (%) 73  (32) 8  (50)  65  (30)  0.1  2.31  (0.83—6.41)
Echocardiographic  parameters
LV  end-diastolic  volume,
ml/BSA
60.3  ±  26.4  65.9  ±  37.0  59.9  ±  25.5  0.4  1.01  (0.99—1.02)
LV end-systolic  volume,
ml/BSA
32.3  ±  24.1  38.9  ±  31.2  31.8  ±  23.5  0.3  1.01  (0.99—1.03)
LV ejection  fraction,  % 50.8  ±  14.8  47.7  ±  17.3  51.1  ±  14.6  0.4  0.99  (0.95—1.02)
LV mass  index,  g/BSA 95.7  ±  28.4  121.8  ±  28.8  93.8  ±  27.5  0.001  1.03  (1.01—1.04) 0.9
Maximal LA  volume,  ml/BSA 52.5  ±  24.0  76.5  ±  41.2  50.7  ±  21.2  0.001  1.03  (1.01—1.05) 0.08
Minimal LA  volume,  ml/BSA 36.9  ±  21.0  59.5  ±  37.4  35.2  ±  18.3  <0.001  1.03  (1.02—1.05)  0.1
LA volume  changes,  % 31.3  ±  12.0  24.5  ±  12.0  31.8  ±  11.9  0.02  0.94  (0.90—0.99)  0.4
E, cm/s 80.0  ±  22.1  86.4  ±  20.8  79.5  ±  22.1  0.2  1.01  (0.99—1.04)
e′,  cm/s  7.1  ±  2.3  5.3  ±  1.5  7.2  ±  2.3  0.002  0.63  (0.47—0.85)  0.07
E/e′ 12.7  ±  6.4  18.6  ±  6.8  12.2  ±  6.1  0.001  1.11  (1.05—1.19)  0.9
Deceleration time,  ms 175  ±  43 175  ±  39 175  ±  44 0.9  1.00  (0.99—1.01)
RV pressure,  mmHg 23.9  ±  8.9  33.5  ±  9.6  23.2  ±  8.4  <0.001  1.09  (1.04—1.15)  0.5
SEC, n  (%) 58  (25) 13  (81) 45  (21) <0.001  16.37  (4.47—59.93)  0.005  79.43  (3.76—1679)
Appendage ﬂow  velocity,
cm/s
29.1  ±  16.2  15.4  ±  12.1  30.1  ±  16.1  0.001  0.89  (0.83—0.95)  0.03  0.81  (0.67—0.98)
PFO or  atrial  septal
aneurysm,  n  (%)
29  (13) 2  (13) 27  (13) 0.9  1.00  (0.21—4.62)
AF, atrial ﬁbrillation; BSA, body surface area; CI, conﬁdence interval; INR, international normalized ratio; LA, left atrium; LAT, left atrial thrombus; LV, left ventricle; PFO, patent foramen
ovale; RV, right ventricle; SEC, spontaneous echocardiographic contrast.
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Table  2  Clinical  and  echocardiographic  parameters  in  patients  with  sufﬁcient  anticoagulation  and  with  sub-therapeutic
anticoagulation.
Sufﬁcient
anticoagulation  (n  =  83)
Sub-therapeutic
anticoagulation  (n  =  148)
p-Value
Age,  years  62  ±  12  65  ±  12  0.2
Male, n  (%)  68  (82)  115  (78)  0.6
Body mass  index  23.0  ±  3.2  23.7  ±  3.7  0.2
Hypertension,  n  (%)  43  (52)  86  (58)  0.9
Diabetes mellitus,  n  (%)  11  (13)  34  (23)  0.1
Heart failure,  n  (%) 29  (35)  60  (41)  0.5
History of  cerebral  ischemia,  n  (%) 13  (16) 20  (14) 0.8
CHADS2 score 1.5  ±  0.4  1.7  ±  1.2  0.2
Paroxysmal  AF,  n  (%) 23  (28) 49  (33) 0.5
Duration  of  anticoagulation  therapy
(>1 year),  n  (%)
17  (20)  41  (28)  0.3
INR 2.4  ±  0.4  1.9  ±  0.7  <0.001
Antiplatelet  therapy,  n  (%)  25  (30)  48  (32)  0.7
Echocardiographic  parameters
LV  end-diastolic  volume,  ml/BSA  61.5  ±  29.0  59.7  ±  24.9  0.6
LV end-systolic  volume,  ml/BSA  33.4  ±  26.4  31.7  ±  22.8  0.6
LV ejection  fraction,  %  50.2  ±  15.0  51.2  ±  14.7  0.6
LV mass  index,  g/BSA  95.5  ±  26.8  95.8  ±  29.3  0.9
Maximal LA  volume,  ml/BSA  50.1  ±  21.0  53.8  ±  25.4  0.3
Minimal LA  volume,  ml/BSA  34.2  ±  18.0  38.4  ±  22.4  0.2
LA volume  changes,  %  32.5  ±  12.0  30.7  ±  12.1  0.3
E, cm/s 79.6  ±  17.6  80.2  ±  24.3  0.9
e′,  cm/s  7.8  ±  2.4  6.7  ±  2.1  <0.001
E/e′ 11.6  ±  5.6  13.3  ±  6.7  0.05
Deceleration  time,  ms 168  ±  41  179  ±  44  0.08
RV pressure,  mmHg 23.7  ±  8.0  24.0  ±  9.4  0.8
LAT, n  (%) 3 (3.6)  13 (8.8)  0.2
SEC, n  (%) 21  (25) 37  (25)  0.9
Appendage ﬂow  velocity,  cm/s 27.6  ±  15.1  29.9  ±  16.8  0.3
PFO, n  (%) 12  (14) 13  (9) 0.2
Atrial septal  aneurysm,  n  (%) 2 (2.4)  2 (1.4)  0.5
AF, atrial ﬁbrillation; BSA, body surface area; INR, international normalized ratio; LA, left atrium; LAT, left atrial thrombus; LV, left
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ncidence  of  LAT  was  signiﬁcantly  higher  in  the  lowest  tertile
INR  <1.83)  than  in  others  (13%,  2.5%,  and  5.2%,  respectively,
 =  0.03).
In  148  patients  with  sub-therapeutic  anticoagulation,  TEE
ound  LAT  in  13  (8.8%)  patients,  whereas  LAT  was  observed
n  3  (3.6%)  of  83  patients  with  sufﬁcient  anticoagulation
p  =  0.2)  (Table  2).  In  patients  with  sub-therapeutic  anti-
oagulation,  there  were  signiﬁcant  differences  in  CHADS2
core,  LV  mass  index,  LA  volume  and  its  changes,  e′,  E/e′,  RV
ressure,  the  presence  of  SEC,  and  LA  appendage  ﬂow  veloc-
ty  between  patients  with  and  without  LAT  (Table  3).  When
hese  signiﬁcant  parameters  in  univariate  analysis  were
ntered  into  the  multivariate  stepwise  logistic  regression
nalysis,  higher  CHADS2 score  (p  =  0.02),  decreased  LA  vol-
me  changes  (p  =  0.03)  and  the  presence  of  SEC  (p  =  0.008)
ere  independent  determinants  for  LAT.
Clinical  and  echocardiographic  ﬁndings  of  patients  with
AT  after  sufﬁcient  anticoagulation  are  summarized  in
able  4.  All  these  3  patients  were  male  with  permanent  AF
ho  had  decreased  LV  systolic  and  diastolic  function  and
b
r
L
deous echocardiographic contrast.
ilated  LA  on  TTE  and  SEC  and  reduced  appendage  ﬂow
elocity  on  TEE.
linical  outcome
uring  the  follow-up  period  of  21  ±  16  months,  20  (8.6%)
atients  had  cardiovascular  events,  including  death  in  4
1.7%)  patients,  congestive  heart  failure  in  8  (3.9%)  patients,
troke  in  3  (1.3%)  patient,  acute  coronary  syndrome  in  3
1.3%)  patients,  ventricular  arrhythmia  in  1  (0.4%)  patient,
nd  arterial  embolism  in  1  (0.4%)  patient.  Four  patients
ied  due  to  arrhythmia  in  2  patients,  heart  failure  in  1
atient,  and  sudden  death  in  1  patient.  When  the  endpoints
f  this  analysis  were  all-cause  deaths  including  cardiac,
erebral,  vascular  and  other  deaths,  and  cardiac,  cere-
ral  and  vascular  events,  the  multivariate  stepwise  logistic
egression  analysis  found  higher  CHADS2 score  and  larger
V  end-diastolic  volume  as  independent  factors  for  car-
iovascular  events  (Table  5).  By  Kaplan—Meier  analysis,
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Table  3  Clinical  and  echocardiographic  parameters  in  patients  with  sub-therapeutic  anticoagulation.
LAT  (+)  (n  =  13) LAT  (−)  (n  =  135)  Univariate  analysis Multivariate  analysis
p-Value Odds  ratio  (95%  CI) p-Value Odds  ratio  (95%  CI)
Age,  years 70  ±  9 64  ±  12 0.07  1.06  (0.99—1.12)
Male, n  (%) 9  (69) 106  (79) 0.4  0.62  (0.18—2.14)
Body mass  index 23.4  ±  3.7  23.7  ±  3.7  0.8  0.98  (0.83—1.15)
Hypertension,  n  (%) 9  (69) 77  (57) 0.4  1.67  (0.50—5.78)
Diabetes mellitus,  n  (%) 5  (38) 29  (21) 0.2  2.28  (0.70—7.51)
Heart failure,  n  (%) 8  (62) 52  (39) 0.1  2.55  (0.79—8.23)
History of  cerebral  ischemia,  n
(%)
2  (15) 18  (13) 0.8  1.18  (0.24—5.77)
CHADS2 score 2.5  ±  1.1  1.6  ±  1.2  0.02  1.81  (1.13—2.92) 0.02  2.89  (1.21—6.93)
Paroxysmal AF,  n  (%) 2  (15) 47  (35) 0.2  0.34  (0.07—1.60)
Duration of  anticoagulation
therapy  (>1  year),  n  (%)
6  (46) 35  (26) 0.1  2.45  (0.77—7.78)
INR 1.7 ±  0.4  1.9  ±  0.7  0.4  0.53  (0.11—2.50)
Antiplatelet  therapy,  n  (%) 7  (54) 41  (30)  0.09  2.68  (0.85—8.45)
Echocardiographic  parameters
LV  end-diastolic  volume,
ml/BSA
61.0  ±  32.3  59.5  ±  24.2  0.8  1.00  (0.98—1.03)
LV end-systolic  volume,  ml/BSA 32.7  ±  25.5  31.6  ±  22.6  0.9  1.00  (0.98—1.03)
LV ejection  fraction,  % 52.1  ±  15.6  51.1  ±  14.6  0.8  1.01  (0.97—1.05)
LV mass  index,  g/BSA 121.0  ±  32.0  93.4  ±  28.0  0.003  1.03  (1.01—1.04) 0.5
Maximal LA  volume,  ml/BSA 80.4  ±  45.0  51.3  ±  21.2  0.002  1.03  (1.01—1.05) 0.5
Minimal LA  volume,  ml/BSA 63.3  ±  40.8  36.0  ±  18.4  0.001  1.04  (1.02—1.06) 0.4
LA volume  changes,  % 23.9  ±  13.1  31.3  ±  11.8  0.04  0.94  (0.89—0.99)  0.03  0.88  (0.78—0.98)
E, cm/s 89.0  ±  21.5  79.3  ±  24.5  0.2  1.02  (0.99—1.04)
e′,  cm/s  5.1  ±  1.4  6.9  ±  2.1  0.005  0.61  (0.43—0.86)  0.2
E/e′ 19.2  ±  7.1  12.7  ±  6.4  0.003  1.12  (1.04—1.20)  0.5
Deceleration time,  ms 185  ±  37 178  ±  45 0.60  1.00  (0.99—1.02)
RV pressure,  mmHg 33.2  ±  10.5  23.2  ±  8.8  0.003  1.08  (1.03—1.14)  0.7
SEC, n  (%) 10  (77) 27  (20) <0.001  13.33  (3.43—51.82)  0.008  23.87  (2.32—245.4)
Appendage ﬂow  velocity,  cm/s 16.4  ±  13.4  31.2  ±  16.6  0.007  0.91  (0.85—0.98)  0.06
PFO or  atrial  septal  aneurysm,
n (%)
1 (7.7)  14  (10) 0.7  0.72  (0.09—5.96)
AF, atrial ﬁbrillation; BSA, body surface area; CI, conﬁdence interval; INR, international normalized ratio; LA, left atrium; LAT, left atrial thrombus; LV, left ventricle; PFO, patent foramen
ovale; RV, right ventricle; SEC, spontaneous echocardiographic contrast.
272  S.  Fukuda  et  al.
Table  4  Clinical  and  echocardiographic  parameters  in  patients  with  LAT  after  sufﬁcient  anticoagulation.
Patient  1  Patient  2  Patient  3
Age,  years  68  72  73
Gender Male  Male  Male
Body mass  index  17.5  19.9  25.4
Hypertension  Yes  No  No
Diabetes mellitus  No  No  No
Heart failure Yes  No  Yes
History of  cerebral  ischemia Yes No  Yes
CHADS2 score 4 0 3
Paroxysmal  AF No No No
Duration  of  anticoagulation  therapy 1  year 6  month 1  year
INR 2.5  2.5  2.3
Antiplatelet  therapy  No  No  Aspirin
Echocardiographic  parameters
LV  end-diastolic  volume,  ml/BSA  128  23  110
LV end-systolic  volume,  ml/BSA  98  14  86
LV ejection  fraction,  %  23  40  22
LV mass  index,  g/BSA  131  115  129
Maximal LA  volume,  ml/BSA  67  54  57
Minimal LA  volume,  ml/BSA  44  41  44
LA volume  changes,  %  34  24  44
E, cm/s  89  58  79
e′,  cm/s  8.3  3.5  5.8
E/e′ 15.7  16.6  13.6
Deceleration  time,  ms 130 150  130
RV pressure,  mmHg 40  29  36
SEC, n  (%)  Yes  Yes  Yes
Appendage ﬂow  velocity,  cm/s 8.4  11  15
PFO or  atrial  septal  aneurysm No No  Atrial  septal  aneurysm
Events (follow-up  period  or  event  date) Death  for  arrhythmia
(2  months)
No  (4.6  years) No  (4.5  years)
AF, atrial ﬁbrillation; BSA, body surface area; INR, international normalized ratio; LA, left atrium; LAT, left atrial thrombus; LV, left
ventricle; PFO, patent foramen ovale; RV, right ventricle; SEC, spontaneous echocardiographic contrast.
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cvent-free  survival  was  signiﬁcantly  worse  for  patients  with
AT  compared  with  those  without  LAT  (p  =  0.02)  (Fig.  3A).
aplan—Meier  analysis  was  then  repeated  excluding  con-
estive  heart  failure  (n  =  8)  and  the  death  related  to
eart  failure  (n  =  1)  from  the  cardiovascular  events.  In  the
esulting  analysis,  patients  with  LAT  had  worse  outcomes
ompared  with  those  without  LAT  (p  =  0.009)  (Fig.  3B).  Sim-
lar  results  were  obtained  in  the  relationship  between  the
resence  of  LAT  and  a  CHADS2 score  (Fig.  3C  and  D).
LAT  was  observed  in  4  (3.3%)  of  120  patients  with  a
HADS2 score  of  0  or  1,  including  3  patients  with  sub-
herapeutic  anticoagulation  and  1  patient  with  sufﬁcient
nticoagulation.  On  the  other  hand,  LAT  was  not  present  in
9  (89%)  of  111  patients  with  a  CHADS2 score  ≥2.  Impor-
antly,  these  patients  with  either  LAT  or  a  CHADS2 score
2  had  comparable  outcome  to  that  with  low  CHADS2 score
ithout  LAT,  and  was  better  than  that  with  both  LAT  and  a
HADS2 score  ≥2  (all  p  <  0.05),  as  shown  in  Fig.  4.
In  231  patients,  intra-atrial  shunting  by  patent  foramen
vale  (PFO)  and  atrial  septal  aneurysm  were  observed  in  25
11%)  patients  and  4  (1.7%)  patients,  respectively  (Table  1).
he  presence  of  PFO  or  atrial  septal  aneurysm  was  not
w
p
pssociated  with  either  the  presence  of  LAT  or  the  cardio-
ascular  outcomes,  as  shown  in  Tables  1  and  5,  respectively.
hen  the  congestive  heart  failure  and  the  death  related  to
eart  failure  were  excluded  from  the  events,  the  presence
f  PFO  or  atrial  septal  aneurysm  remained  to  be  insigniﬁcant
or  the  events  (p  =  0.6).
iscussion
n  this  study,  TEE  found  LAT  in  8.8%  of  patients  with  non-
alvular  AF  with  sub-therapeutic  anticoagulation  therapy,
hereas  LAT  was  observed  in  3.6%  of  patients  with  sufﬁcient
nticoagulation  therapy.  The  presence  of  LAT  was  associated
ith  higher  CHADS2 score,  decreased  LA  volume  changes
nd  the  presence  of  SEC  in  patients  with  sub-therapeutic
nticoagulation.  Importantly,  the  presence  of  LAT  after  anti-
oagulation  therapy  was  a  univariate  risk  factor  associated
ith  worse  outcomes.
AF  is  the  most  common  arrhythmia  seen  in  clinical
ractice  [1].  Previous  studies  have  demonstrated  that
atients  with  AF  have  a  four-  to  ﬁve-fold  increased
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Table  5  Comparison  of  clinical  and  echocardiographic  parameters  between  patients  with  and  without  cardiovascular  events.
Events  (+)  (n  =  20) Events  (−)  (n  =  211)  Univariate  analysis Multivariate  analysis
p-Value Odds  ratio  (95%  CI) p-Value Odds  ratio  (95%  CI)
Age,  years 70  ±  12 63  ±  12 0.01  1.06  (1.01—1.11) 0.2
Male, n  (%) 13  (65) 170  (81) 0.1  0.44  (0.17—1.89)
Body mass  index 22.1  ±  3.1  23.6  ±  3.6  0.07  0.87  (0.75—1.01)
Hypertension,  n  (%) 12  (60) 117  (55) 0.7  1.21  (0.47—3.07)
Diabetes mellitus,  n  (%) 8  (40) 37  (18) 0.02  3.14  (1.20—8.21) 0.2
Heart failure,  n  (%) 13  (65) 76  (36) 0.02  3.30  (1.26—8.62) 0.6
History of  cerebral  ischemia,  n  (%) 7  (35) 26  (12) 0.009  3.83  (1.40—10.48) 0.4
CHADS2 score 2.8  ±  1.4  1.5  ±  1.2  <0.001  2.21  (1.49—3.26) <0.001  2.34  (1.49—3.66)
Paroxysmal AF,  n  (%) 4  (20) 68  (32) 0.3  0.53  (0.17—1.63)
Duration of  anticoagulation  therapy  (>1  year),  n  (%) 5  (25) 53  (25) 0.9  0.99  (0.35—2.87)
INR 2.0 ±  0.4  2.1  ±  0.7  0.6  0.78  (0.32—1.91)
Sufﬁcient anticoagulation,  n  (%) 5  (25)  78  (37)  0.3  0.57  (0.20—1.62)
Antiplatelet  therapy,  n  (%) 7  (35)  66  (31)  0.7  1.18  (0.45—3/10)
Echocardiographic  parameters
LV  end-diastolic  volume,  ml/BSA 80.8  ±  46.9  58.4  ±  22.8  0.002  1.02  (1.01—1.04)  0.02  1.02  (1.01—1.04)
LV end-systolic  volume,  ml/BSA 51.4  ±  40.6  30.5  ±  21.2  0.001  1.03  (1.01—1.04) 0.9
LV ejection  fraction,  % 42.3  ±  14.0  51.7  ±  14.6  0.008  0.96  (0.93—0.99)  0.8
LV mass  index,  g/BSA 109.5  ±  30.9  94.4  ±  27.9  0.03  1.02  (1.01—1.03) 0.2
Maximal LA  volume,  ml/BSA 56.0  ±  19.5  52.1  ±  24.3  0.5  1.01  (0.99—1.02)
Minimal LA  volume,  ml/BSA 39.6  ±  15.4  36.6  ±  21.5  0.5  1.01  (0.99—1.03)
LA volume  changes,  % 30.6  ±  11.0  31.4  ±  12.2  0.8  0.99  (0.96—1.03)
E, cm/s 93  ±  26.5 78.7  ±  21.2  0.007  1.03  (1.01—1.05)  0.05
e′,  cm/s  6.2  ±  1.9  7.2  ±  2.3  0.06  0.80  (0.63—1.01)
E/e′ 18.1  ±  9.2  12.2  ±  5.8  0.001  1.11  (1.05—1.18)  0.08
Deceleration time,  ms 175  ±  51 175  ±  43 0.9  1.00  (0.99—1.01)
RV pressure,  mmHg 27.7  ±  10.5  23.5  ±  8.6  0.05  1.04  (1.00—1.09)
SEC, n  (%) 7  (35) 51  (24) 0.3  1.69  (0.64—4.46)
LAT, n  (%) 4  (20) 12  (6)  0.03  4.15  (1.20—14.34)  0.3
Appendage ﬂow  velocity,  cm/s 22.5  ±  14.9  29.7  ±  16.2  0.07  0.97  (0.93—1.01)
PFO or  atrial  septal  aneurysm,  n  (%) 3  (15) 26  (12)  0.7  1.26  (0.34—4.58)
AF, atrial ﬁbrillation; BSA, body surface area; CI, conﬁdence interval; INR, international normalized ratio; LA, left atrium; LAT, left atrial thrombus; LV, left ventricle; PFO, patent foramen
ovale; RV, right ventricle; SEC, spontaneous echocardiographic contrast.
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Figure  3  Kaplan—Meier  curves  showing  cumulative  proportion  of  patients  without  cardiovascular  events  during  follow-up.  (A)  LAT
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end all-cause  events.  (B)  LAT  and  events  excluding  congestive
core  and  events  excluding  congestive  heart  failure.  LAT,  left  a
isk  of  stroke,  resulting  in  considerable  morbidity  and
ortality  [2—4]. Anticoagulation  therapy  is  the  most  effec-
ive  antithrombotic  therapy  for  stroke  prophylaxis  for
atients  at  high  risk  of  stroke  [20]. Prior  large  stud-
es  have  demonstrated  an  approximately  70%  reduction
n  the  risk  of  thromboembolic  events  through  antico-
gulation  therapy  [5,6], which  indicates  that,  in  the
emaining  30%  of  AF  patients,  anticoagulation  therapy
ay  not  be  effective  in  preventing  thromboembolic
vents.
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igure  4  Kaplan—Meier  curves  showing  cumulative  proportion  of  pa
ere divided  into  3  subgroups  according  to  the  presence  of  LAT  and
vents. (B)  Events  excluding  congestive  heart  failure.rt  failure.  (C)  CHADS2 score  and  all-cause  events.  (D)  CHADS2
thrombus.
The  LA,  especially  its  appendage,  is  the  presumed  site
f  thrombus  formation  and  a  source  of  arterial  throm-
oembolisms.  TEE  has  clear  advantages  over  TTE  and  other
maging  modalities  in  the  investigation  of  the  LA  appendage.
n  previous  investigations  using  TEE,  LAT  was  observed  in
0—30%  of  patients  with  AF  [7—12]. In  clinical  practice,  most
atients  who  undergo  TEE  prior  to  cardioversion  from  AF  are
eferred  because  (a)  they  have  not  been  on  anticoagulants
nd  expedited  cardioversion  is  deemed  desirable,  or  (b)
hey  have  been  inadequately  anticoagulated  and  delaying
tients  without  cardiovascular  events  during  follow-up.  Patients
/or  a  CHADS2 score  ≥2.  LAT,  left  atrial  thrombus.  (A)  All-cause
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is  deemed  inappropriate,  or  (c)  a  prior  TEE  has  shown  a  LAT
and  reassessment  is  needed  [21]. Therefore,  TEE  was  not
routinely  performed  in  patients  with  short-term  AF  (<48  h)
or  after  sufﬁcient  anticoagulation  therapy  (>3  weeks)  in
clinical  practice.  However,  for  example,  Kleemann  et  al.
reported  that  LAT  was  present  in  4%  of  patients  with  short-
term  AF  (<48  h)  who  did  not  take  anticoagulation  therapy
[22].
Little  is  known  about  the  incidence  of  LAT  after  anticoag-
ulation  therapy.  Collins  et  al.  performed  TEE  examinations
before  and  after  4-week  anticoagulation  therapy  and  inves-
tigated  the  outcomes  of  thrombus  formation  in  18  patients
with  nonvalvular  AF  [23]. They  found  that  the  thrombus
was  resolved  in  16  (89%)  patients,  whereas  the  throm-
bus  remained  in  2  (11%)  patients.  In  the  study  by  Seidl
et  al.,  LAT  was  detected  in  7.7%  of  patients  with  INR  of
2—3  [24]. In  contrast,  a  higher  incidence  of  LAT  in  patients
with  sub-therapeutic  anticoagulation  has  been  reported
(9.9%  of  patients  with  anticoagulation  therapy  with  INR  less
than  2.0)  [25]. It  was  consistent  with  previous  observa-
tions  that  suboptimal  intensity  of  anticoagulation  therapy
was  one  of  the  risks  for  LAT  and  stroke  [13,25].  Because
these  investigations  suggested  the  presence  of  residual
LAT  even  after  >3  weeks  of  sufﬁcient  anticoagulation,  TEE
examination  was  routinely  performed  for  all  AF  patients
before  cardioversion  in  our  institutions.  As  a  result,  we
conﬁrmed  that  LAT  was  observed  in  3.6%  of  patients  with
sufﬁcient  anticoagulation  and  8.8%  of  patients  with  sub-
therapeutic  anticoagulation  in  same  study  population  in  this
study.
We  divided  the  study  population  into  2  groups  according
to  the  intensity  of  anticoagulation  therapy,  because  ana-
lyzing  patients  with  inadequate  anticoagulation  in  order
to  determine  which  additional  factors  (echocardiographic
and/or  clinical  parameters)  might  help  identify  those
patients  in  whom  LAT  actually  develop.  Also,  we  studied
patients  in  whom  anticoagulation  therapy  was  therapeutic
to  determine  why  some  of  these  patients  developed  LAT.  In
the  present  study,  higher  CHADS2 score,  decreased  LA  vol-
ume  changes,  and  the  presence  of  SEC  were  identiﬁed  as
factors  associated  with  LAT  when  anticoagulation  therapy
was  insufﬁcient.  These  ﬁndings  were  supported  by  the  pre-
vious  observations  that  CHADS2 score  and  the  presence  of
SEC  were  risks  for  stroke  and  total  mortality  [15,26,27].
Also,  decreased  LA  volume  changes  might  contribute  to
the  blood  stasis  in  LA  and  concomitant  LAT  formation.  It
is  therefore  indicated  that  sufﬁcient  anticoagulation  ther-
apy  with  INR  ranges  up  to  2.0  at  least  for  3  weeks  was
important,  especially  in  patients  with  severe  AF  in  whom
high  CHADS2 score  or  echocardiographic  parameters  sug-
gesting  LA  blood  stasis  was  observed.  On  the  other  hand,
LAT  was  observed  after  >3  weeks  of  sufﬁcient  anticoag-
ulation  in  3.6%  of  patients  who  had  both  LV  systolic  and
diastolic  dysfunction.  More  aggressive  anticoagulation  ther-
apy  than  those  usually  recommended  might  be  necessary
for  these  patients.  Furthermore,  we  found  the  presence
of  LAT  as  a  risk  factor  for  the  cardiovascular  outcomes.
Therefore,  considering  the  safety  of  TEE  [28], routine  TEE
before  cardioversion  could  be  performed  to  conﬁrm  the
presence  or  absence  of  LAT,  which  would  provide  important
information  for  decision  making  of  cardioversion  and  future
outcomes.
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This  study  showed  that  the  presence  of  atrial  septal
neurysm  or  inter-atrial  shunting  had  no  effect  on  LAT  for-
ation  or  cardiovascular  outcomes  in  AF  patients  receiving
nticoagulation  therapy,  which  was  consistent  with  a  pre-
iously  reported  ﬁnding  that  these  anatomic  abnormalities
id  not  increase  the  risk  of  stroke  or  death  in  patients  who
ad  received  aspirin  or  warfarin  therapy  [29]. These  results
uggest  that  anticoagulation  therapy  might  be  effective  in
reventing  LAT  formation  and  cardiovascular  events  associ-
ted  with  these  anatomic  abnormalities.
tudy  limitations
here  were  several  limitations  in  this  study.  First,  the  num-
er  of  patients  was  relatively  small,  especially  in  patients
ith  LAT  after  sufﬁcient  anticoagulation  (n  =  3).  Therefore,
tatistical  analysis  was  not  performed  to  identify  a  group  at
igh  risk  in  whom  INR  targets  should  be  higher  than  those
sually  recommended.  Furthermore,  it  was  a  retrospective
nalysis  of  a  highly  selected  population  from  two  different
nstitutions.  Further  prospective  studies  should  be  done  to
onﬁrm  the  results  of  this  study  with  a  much  larger  popula-
ion.
Second,  approximately  30%  of  patients  had  persistent  AF
f  >1  year,  which  might  result  in  enlarged  LA  size.  In  fact,
aximal  LA  volume  index  was  52.5  ±  24.0  ml/BSA.  Although
-dimensional  echocardiography  is  widely  used  in  clinical
ractice,  three-dimensional  imaging  techniques  might  pro-
ide  more  accurate  quantiﬁcation  of  LV  and  LA  volumes  and
unction  [30,31].
Finally,  other  factors  may  have  caused  the  thromboem-
olic  events,  although  the  presence  of  LAT  was  clearly
ssociated  with  the  increased  risk  of  thromboembolic  events
nd  outcomes  in  patients  with  AF.  For  example,  in  16
atients  with  LAT,  cardioversion  was  not  performed,  fol-
owing  by  anticoagulation  therapy.  However,  in  215  patients
ithout  LAT,  183  (85%)  patients  had  succeeded  cardiover-
ion,  and  anticoagulation  therapy  was  ended  thereafter.
hus,  in  addition  to  the  presence  of  LAT,  the  outcomes
ight  be  associated  with  its  indirect  effects,  such  as  persis-
ent  AF  and/or  concomitant  medications.  Also,  the  duration
f  anticoagulation  therapy  was  not  an  independent  factor
or  the  presence  of  LAT.  However,  the  accurate  duration  of
he  therapeutic  range  was  unclear,  especially  in  patients
ith  sub-therapeutic  anticoagulation,  because  laboratory
xamination  was  performed  1  or  2  times  a month.  Closer
onitoring  of  laboratory  examination  might  provide  the
nswer  in  this  question.
onclusions
his  study  demonstrated  that  LAT  was  a  univariate  risk  factor
ssociated  with  worse  cardiovascular  outcomes,  which  was
bserved  in  8.8%  of  patients  with  sub-therapeutic  anticoag-
lation  and  3.6%  of  patients  with  sufﬁcient  anticoagulation,
espectively.  This  ﬁnding  suggested  the  importance  of  sufﬁ-
ient  anticoagulation  therapy  with  INR  ranges  up  to  2.0  at
east  for  3  weeks,  as  well  as  the  use  of  TEE  examination  in
atients  with  AF  prior  to  cardioversion.
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